Latest News- HIV Drugs Market: Offline is expected to lead the Distribution Channel segment during 2024-2028

The HIV Drugs Market is being driven by Increasing prevalence of HIV AIDS worldwide

The HIV Drugs Market is expected to grow at a CAGR of 5.02% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 9.99 billion. The global HIV drugs market has witnessed a significant shift towards expanding access to life-saving Antiretroviral Therapy (ART) for people living with HIV, irrespective of their geographical location or socio-economic status. This trend is driven by increased funding and resources from governments, international organizations, and NGOs, leading to enhanced healthcare infrastructure, improved systems, and the availability of HIV drugs, particularly in low- and middle-income countries. Additionally, the production and distribution of generic versions of HIV drugs have been instrumental in broadening treatment access. 

Get more information on HIV Drugs Market by requesting a sample report

Which Factors Are Causing a Surge in Market Growth?

The market is segmented based on

• Distribution Channel
  • Offline
  • Online
• Therapy
  • Combination HIV medicines
  • Integrase inhibitors
  • Non-nucleoside reverse transcriptase inhibitors
  • Others
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • China
  • Rest of World (ROW)

According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows: 

• Increasing prevalence of HIV AIDS worldwide
• Increasing cases of associated risk factors
• Surge in geriatric population

However, the market also witnesses some limitations, which are as follows:

• Drug resistance among individuals
• Underdiagnosis of HIV
• Preference for substitute treatment options

Benefits of Buying Global HIV Drugs Market Research Report by Technavio

Rich Experience: 20+ years leading global market research, trusted insights across industries.

Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.

Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.

Market Scope in HIV Drugs Market Research Report

Find out which segment is leading the market by accessing the free PDF report

Research Analysis Overview

The HIV drugs market encompasses a range of medications used to treat HIV, a viral infection with a significant global prevalence. Key HIV drugs include Atripla, Complera, Prezcobix, Stribild, Genvoya, Odefsey, Symtuza, Triumeq, Descovy, Dovato, Emtriva, Epivir, Epzicom, and Efavirenz tablets. New product launches continue in this sector, with CD4 cells playing a crucial role in HIV infection progression. Import and export of HIV medications are integral to the healthcare products industry, serving a growing patient population undergoing testing procedures for HIV.

Market Research Overview

The global pharmaceuticals market encompasses entities involved in the research and development (R&D) or manufacturing of various types of drugs, including HIV drugs, and covers both generic and non-generic offerings. According to Technavio, the healthcare market size is determined by the collective revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the growth of the pharmaceuticals sector include the increasing global population aging, with the number of individuals over 60 years old in the US projected to reach nearly one-quarter by 2050, and Europe anticipated to reach a similar ratio by 2030. This demographic shift will lead to a higher demand for treatments, including HIV drugs such as Atripla, Complera, Prezcobix, Stribild, and Genvoya.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/